

POLYCEF TABLET

Generic Name:	Cefuroxime Axetil
Category:	Antibacterial (Second generation Cephalosporin)
Composition/Presentation:	POLYCEF 250 Each tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 250 mg
	POLYCEF 500 Each tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 500 mg
	POLYCEF 125 Kid Tablet Each dispersible tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 125 mg Supplied in ALU-ALU blister pack of 10 Tablets x 10 Blisters

MECHANISM OF ACTION

Cephalosporin disrupts the synthesis of the peptidoglycan layer of bacterial cell wall.

INDICATIONS

- Pharyngitis/Tonsillitis
- Acute Bacterial Otitis Media
- Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial infections of Acute Bronchitis
- Uncomplicated skin and skin-structure infections
- Uncomplicated urinary tract infections
- Uncomplicated gonorrhea, urethral and endocervical infections
- Early Lyme disease (Erythema migrans)

PHARMACOKINETICS

- Bioavailability: 37% on empty stomach, up to 52% if taken after food
- Metabolism: axetil moiety is metabolized to acetaldehyde and acetic acid
- Half life: 80 minutes
- Excretion: Urine 66-100% Unchanged

DOSAGE

- **Pharyngitis/Tonsillitis:** 250mg B.I.D for 10 days.
- **Acute bacterial maxillary sinusitis:** 250 mg B.I.D. for 10 days
- **Acute bacterial exacerbations of chronic bronchitis:** 250 or 500 mg B.I.D. for 10 days
- **Secondary bacterial infections of acute bronchitis:** 250 or 500 mg B.I.D. for 5-10 days
- **Uncomplicated skin and skin-structure infections:** 250 or 500 mg B.I.D. for 10 days
- **Uncomplicated urinary tract infections:** 250 mg B.I.D. for 7-10 days.
- **Uncomplicated gonorrhoea:** 1,000 mg once single dose.
- **Early Lyme disease:** 500 mg B.I.D. for 20 days.
- **Acute otitis media:** 250 mg B.I.D. for 10 days. (For pediatric patients who can swallow tablets)
- **Acute bacterial maxillary sinusitis:**250 mg B.I.D. for 10 days.(For pediatric patients who can swallow tablets)

ADVERSE EFFECTS

Diarrhea, loss of appetite, nausea or vomiting, headache, dizziness, fatigue

For further information, please contact:

Market Planning Department

Deurali-Janta Pharmaceuticals Pvt. Ltd.

GPO Box 4239, 355 Hattisar Road, Kamalpokhari, Kathmandu, Nepal.

Tel: 4435167/68/69 E-mail: mplanning@deuralijanta.com Website: www.deuralijanta.com

